Since the discovery that HA receptor, CD44 is a stem cell marker, targeting of CD44 for anti-cancer therapy has been attempted using DNA vaccines, anti-CD44 monoclonal antibodies, and nanoparticle-mediated delivery of CD44siRNAs. This evidence concerns the gene CD44 and cancer.